title: Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
authors.forename: Franck E
authors.initials: FE
authors.lastname: Nicolini
authors.forename: H Jean
authors.initials: HJ
authors.lastname: Khoury
authors.forename: Luke
authors.initials: L
authors.lastname: Akard
authors.forename: Delphine
authors.initials: D
authors.lastname: Rea
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.forename: Janis
authors.initials: J
authors.lastname: Leonoudakis
authors.forename: Adam
authors.initials: A
authors.lastname: Craig
authors.forename: Annie-Claude
authors.initials: AC
authors.lastname: Benichou
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000502:physiology; D005500:Follow-Up Studies; D006248:Harringtonines / Q000494:pharmacology / Q000627:therapeutic use*; D000077863:Homoharringtonine; D006801:Humans; D015465:Leukemia, Myeloid, Accelerated Phase / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015996:Survival Rate / Q000639:trends
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D006248:Harringtonines; D047428:Protein Kinase Inhibitors; D000077863:Homoharringtonine; D011505:Protein-Tyrosine Kinases
keywords: advanced chronic myeloid leukemia; dasatinib; homoharringtonine; imatinib; nilotinib; omacetaxine; tyrosine kinase inhibitors